Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ANMCO Research Center, Heart Care Foundation, Florence, Italy.
Int J Cardiol. 2025 Jan 1;418:132601. doi: 10.1016/j.ijcard.2024.132601. Epub 2024 Sep 28.
The clinical governance of patients with acute myocardial infarction (AMI) has markedly changed in the last few years. We sought to assess the contemporary in-hospital management patterns of patients with AMI at a country level.
EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units)-2 was a nationwide, prospective registry aimed to evaluate the current management of patients admitted to intensive cardiac care units (CCUs) for an AMI in Italy.
Over a 4-week period (February 1st-29th, 2024), 183 CCUs enrolled 2806 consecutive patients: 52.6 % with non-ST elevation myocardial infarction (NSTEMI) and 47.4 % with ST-elevation myocardial infarction (STEMI). The median time from hospital admission to angiography in NSTEMI was 22.3 h (IQR 10.9-46.1), while for STEMI was 1.1 h (IQR 0.5-2.2) with significant difference between hospitals with and without catheterization laboratories. In both NSTEMI and STEMI patients, percutaneous coronary intervention (PCI) was the preferred management strategy (73.3 % and 94.2 %, respectively). An optimal secondary prevention therapy, including dual antiplatelet therapy, inhibition of the renin-angiotensin system, a beta-blocker and a high-intensity statin was prescribed at discharge in more than 75 % of patients with AMI. In-hospital major bleedings occurred in 2.0 % and 2.3 % (p = 0.58), while death in 1.8 % and 2.8 % (p = 0.09) of NSTEMI and STEMI patients, respectively.
The EYESHOT-2 registry shows the current management strategies and outcome of AMI patients admitted to Italian CCUs and provides insights to improve the clinical care of such patients.
URL: http://www.
gov. Unique identifier: NCT06316128.
近年来,急性心肌梗死(AMI)患者的临床治理发生了显著变化。我们旨在评估该国 AMI 患者的住院管理模式。
EYESHOT(意大利心脏护理单位住院的急性冠脉综合征患者的使用抗血栓治疗)-2 是一项全国性、前瞻性登记研究,旨在评估意大利因 AMI 入住重症监护病房(CCU)的患者的当前管理情况。
在 4 周期间(2024 年 2 月 1 日至 29 日),183 个 CCU 收治了 2806 例连续患者:52.6%为非 ST 段抬高型心肌梗死(NSTEMI),47.4%为 ST 段抬高型心肌梗死(STEMI)。NSTEMI 患者从入院到血管造影的中位时间为 22.3 小时(IQR 10.9-46.1),而 STEMI 患者为 1.1 小时(IQR 0.5-2.2),具有导管实验室的医院之间存在显著差异。在 NSTEMI 和 STEMI 患者中,经皮冠状动脉介入治疗(PCI)是首选的治疗策略(分别为 73.3%和 94.2%)。超过 75%的 AMI 患者出院时接受了包括双联抗血小板治疗、肾素-血管紧张素系统抑制、β受体阻滞剂和高强度他汀类药物在内的最佳二级预防治疗。NSTEMI 和 STEMI 患者住院期间大出血分别为 2.0%和 2.3%(p=0.58),死亡分别为 1.8%和 2.8%(p=0.09)。
EYESHOT-2 登记研究显示了意大利 CCU 收治的 AMI 患者的当前管理策略和结局,并为改善此类患者的临床护理提供了思路。
URL:http://www.。
gov。独特标识符:NCT06316128。